Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rimegepant in Migraine Prevention in Children and Adolescents
NCT05156398Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Feb 2022
- Primary completion
- Mar 2029
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of rimegepant in migraine, sponsored by Pfizer. Started Feb 2022; status: recruiting.
02
Drugs
rimegepant
03
Conditions
migraine
Beyond the preview
Go deeper on NCT05156398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05156398.